34th CINP World Congress of Neuropsychopharmacology

Call for Abstracts

Abstract Submission is now open!

The Scientific Program Committee for the 34th CINP World Congress of Neuropsychopharmacology (CINP 2023) is inviting the submission of scientific abstracts. 

Important Deadlines

Call for Abstracts Submission Opens1 December 2022
Abstract Submission Deadline15 February 2023
Notification of Acceptance/Rejection8 March 2023
Deadline for Change of Title/Authorship24 March 2023
Presenting Author Registration Deadline24 March 2023
  • Abstracts will be accepted in English only
  • All abstracts must not exceed 500 words
  • A table or figure will count as 150 words
  • The total word count does not include the title, authors’ details or references
  • The name of the presenting author must appear first in the list of authors
  • An international panel of reviews will review all abstracts anonymously
  • There is no fee for submitting an abstract
  • There is no limit to the number of poster abstracts you may submit
  • CINP recommends using the NbN nomenclature for psychotropics (http://nbn2r.com)

Abstract submissions must be structured with the following:

  • Background
  • Aims & Objectives
  • Method
  • Results
  • Discussion  & Conclusion
  • References – Use Harvard style, where each reference is numbered in order of use
  • Keywords – Mandatory to include three
  • Oral Presentation: A limited number of abstracts will be selected as 15-min oral presentations (12 minutes presentation plus 3 minutes of Q&A) in one of the Oral Abstract sessions. If you are not comfortable providing an oral presentation, please only select poster presentation during submission.
  • Poster Presentation: Abstracts not selected for oral presentation will be provided a poster presentation. Top rated posters will be selected as 5-minute presentations (3 minutes presentation plus 2 minutes Q&A) in one of the Data Blitz sessions.

The CINP International Scientific Programme Committee welcomes abstratcs that link the latest, and ground-breaking, preclinical developments with the clinical research on a given topic. Through the free and open exchange of ideas, CINP supports a strong focus on new approaches to the development and assessment of CNS pharmaceuticals by researchers working in both academia and industry. 

Please find below the list of topics: 

Topic 1: Research Topic 2: By Disorder Topic 3: By Drug Methodology
• Clinical • Addiction Disorders • Animal Models
• Preclinical • Anxiety Disorders • Anxiolytics
• Translational • Attention Deficit Disorders • Brain Stimulation
• Others • Autism • Computational Neuroscience
• Bipolar Disorders • Drugs for Bipolar Disorders
• Childhood & Adolescent Disorders • Drugs for Depression
• COVID-19 • Drugs for Insomnia
• Dementia • Drugs for Psychosis
• Depression • Ethics of Psychopharmacology
• Eating Disorders • Genetics
• Epilepsy • History of Psychopharmacology
• Obsessive-Compulsive Disorders • Imaging
• Pain • Molecular Neurobiology/Pharmacology
• Panic Disorders • Neuropathology/Post-Mortem Studies
• Personality Disorders • Neurophysiology
• Post-Traumatic Stress Disorders • Oriental Medicine
• Premenstrual Dysphoric Disorder • Pharmacoeconomics
• Schizophrenia • Pharmacogenetics/Kinetics
• Sexual Disorders • Psychoneuroimmunology
• Sleep Disorders • Transcultural Psychopharmacology
• Suicide • Others
• Others

Contact

If you have any questions regarding abstract submission, please contact the CINP Program Manager at cinp2023-program@cinp.org